{"name":"Paolo Ghia","slug":"paolo-ghia","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOalJMd3BMMlo3Yk84azhUV0NKZDF2UlBud2JnVDNSNHk2LWw5TU0xQnpROUJQUnlIQlg3NTBUZHVpRmVKNGdGdzNPY08yRnJTeHh5bHdHZ0dmYWhmcEtLOVNQdEhwZ2QzV2hsRkZZeC1RclFKXzQwZkxWS1B6RnctVjJQX25leExPTl9UNDJ3MnBMbmdyUnhCUmVyamJFTjRHTVJpQQ?oc=5","date":"2025-03-03","type":"regulatory","source":"PharmTech.com","summary":"EMA Gives Positive Opinion to Lilly Treatment for Chronic Lymphocytic Leukemia - PharmTech.com","headline":"EMA Gives Positive Opinion to Lilly Treatment for Chronic Lymphocytic Leukemia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE5hQ0VBM3hPLURQYV94c2FuYldxbE1ONTdOSW5XMldjVVdScGJNYTlkTWpXVWlWWDZEMkdXNjFieXVkNmZRX2pieGhWN3JERDNWN0hid2JjWjdySFl2clVyWVBmc2laTjZMaUE?oc=5","date":"2024-05-27","type":"pipeline","source":"Wiley Online Library","summary":"First-line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age-matched general population: A pooled post hoc analysis","headline":"First-line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates s","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE84S3hIUnNENk1BV2xWY3A0cUl2eXZwXzJBRWRDQ3lvSVdYTDhfX2VfYmVtQzlsS0JuQ0JkNlpmdVRCSVZTZWJnOXZOOE5vLWJISnVHWC1jUG5HV3dBTi15YUtYZkRmZFJ5aFE?oc=5","date":"2023-10-09","type":"pipeline","source":"Wiley Online Library","summary":"A matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia - Wiley Online Library","headline":"A matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocyt","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQdjJTSTJ5djlKcGZLNW5ISzYta0otNm9CQTJwSE9idWRsaDEwM200b2RKVE9HMER3MDlCcnJPLVlBQmI3UmdMc09DMkhHNDJHY2xKMDNIazdabzZ1VURaOUFzNUVzb25ITGRxaGZqSTNTelZDalNlUmRyemV6aW1SUk9BeW9WeDF0SW8xSjZNbnhLVHdmNnN1MzdjVzhRT281ZVQ2SQ?oc=5","date":"2020-11-09","type":"regulatory","source":"AstraZeneca","summary":"Calquence approved in the EU for the treatment of chronic lymphocytic leukaemia - AstraZeneca","headline":"Calquence approved in the EU for the treatment of chronic lymphocytic leukaemia","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE5JSF84MWV1VkhfbE0tYkEtdWlQVzRQajFpUE4xZGlxdXBCenNYY1ZKdkZma2hSaEVScmFVOFZabm14TWxIQjZsRUZwc1NJN2kyUDZ5ckRB?oc=5","date":"2019-06-28","type":"pipeline","source":"Medscape","summary":"Acalabrutinib Now Finding a Role in CLL, Shows Good Tolerability - Medscape","headline":"Acalabrutinib Now Finding a Role in CLL, Shows Good Tolerability","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}